线粒体NNT在心脏代谢HFpEF中促进透缩功能障碍
Mark E Pepin1,2,3,4,5,6, Philipp J M Konrad1,2,7,3, Sumra Nazir1,2,3
1Medical Faculty Heidelberg, Institute of Experimental Cardiology, Heidelberg University, Germany. (M.E.P., P.J.M.K., S.N., F.B., F.S., M.D., J.B.).
Circulation research
|May 9, 2025
概括
线粒体功能障碍在心力衰竭中发挥着关键作用,具有保存的喷射分数 (HFpEF). 尼古丁胺核酸转酶 (NNT) 和纤维细胞生长因子1 (Fgf1) 被确定为HFpEF的潜在治疗标.
科学领域:
- 心血管研究研究心血管研究
- 线粒体生物学 线粒体生物学
- 代谢性疾病 代谢性疾病
背景情况:
- 由于心力衰竭与保存的喷射分数 (HFpEF) 缺乏有效的疾病修饰疗法.
- 二次命中模型 (高脂肪饮食+L-NAME) 用于研究心脏代谢性HFpEF.
- 在这种模型中,C57BL6/J小鼠显示出有限的透缩功能障碍,需要进一步调查.
研究的目的:
- 调查尼古丁胺核酸转酶 (NNT) 在HFpEF中的作用.
- 在小鼠模型中确定心脏病理是否需要完整的NNT.
- 为了确定HFpEF的潜在治疗点.
主要方法:
- 在C57BL/6N背景上使用野生类型 (Nnt+/+) 和NNT功能丧失 (Nnt-/-) 鼠标建立了一个同源模型.
- 挑战小鼠高脂肪饮食和L-NAME9周.
- 通过心声学评估心脏功能,测量心肌纤维化,并分析代谢物水平 (NAD+,GSH:GSSG) 和基因表达.
主要成果:
- Nnt+/+小鼠表现出减弱的透静放松,病态重塑和心肌纤维化增加.
- 在Nnt+/+小鼠中观察到NAD+和GSH:GSSG比率的显著降低.
- 单核连接体受体分析涉及纤维细胞生长因子1 (Fgf1) 作为一个NNT依赖的介质.
结论:
- 线粒体功能障碍,特别是涉及NNT,在HFpEF病变发生过程中至关重要.
- NNT和Fgf1成为治疗HFpEF的新型治疗点.
- 这项研究为 HFpEF 背后的分子机制提供了关键的见解.
更多相关视频
08:12Author Spotlight: Unveiling Mitochondrial Function and Cellular Metabolic Adaptation in Metabolic Diseases
Published on: October 4, 2024
1.4K
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
107
相关概念视频
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:23Imbalances in Cardiac Output
1.2K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to...
1.2K
01:45Mitochondrial Membranes
6.6K
A single mitochondrion is a bean-shaped organelle enclosed by a double-membrane system. The outer membrane of mitochondria is smooth and contains many porins - the integral membrane transporters. Porins enable free diffusion of ions and small uncharged molecules through the outer mitochondrial membrane but limit the transport of molecules larger than 5000 Daltons. Further, the outer mitochondrial membrane forms a unique structure called membrane contact sites with other subcellular organelles,...
6.6K
01:37Mitochondria
8.9K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
8.9K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
321
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321